Pegasys (Peginterferon alfa-2a) still available in the long term

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：431 / 431
页数：1
相关论文
共 50 条
  • [1] Pegasys (Peginterferon alfa-2a) will continue to be available in the long term
    不详
    VISCERAL MEDICINE, 2021, 37 (04) : 324 - 324
  • [2] Pegasys - Peginterferon alfa-2a - Roche
    不详
    FORMULARY, 2002, 37 (12) : 611 - 612
  • [3] Peginterferon alfa-2a (Pegasys) for chronic hepatitis C
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1151): : 19 - 20
  • [4] The elderly have a comparable exposure and pharmacodynamics of a branched 40KDA peginterferon alfa-2A (Pegasys™).
    Martin, NE
    Sy, S
    Modi, M
    Ho
    GASTROENTEROLOGY, 2000, 118 (04) : A1466 - A1466
  • [5] Extended Peginterferon Alfa-2a (Pegasys) Therapy in Chinese Patients With HBeAg-Negative Chronic Hepatitis B
    Chen, Xuefu
    Chen, Xiaoping
    Chen, Wenli
    Ma, Xiaojun
    Huang, Jing
    Chen, Ren
    JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (10) : 1705 - 1713
  • [6] Efficacy and safety of peginterferon alfa-2a (Pegasys®) combination therapies in patients who relapsed on Rebetron™ therapy.
    Herrine, SK
    Brown, R
    Esposito, S
    Bernstein, DE
    Te, H
    Galati, JS
    Lok, AS
    Ondovik, MS
    Lentz, E
    Harb, GE
    HEPATOLOGY, 2002, 36 (04) : 358A - 358A
  • [7] Enhanced virological response to treatment with 40 kDa peginterferon alfa-2a (PEGASYS®) in patients previously unresponsive to treatment with interferon alfa-2a.
    Minuk, GY
    Reddy, KR
    Lee, SS
    Heathcote, EJ
    O'Grady, J
    Pockros, PJ
    Shiffman, ML
    Naoumov, NV
    Sedarati, F
    Depamphilis, J
    HEPATOLOGY, 2001, 34 (04) : 330A - 330A
  • [8] Combination of Levovirin (LVV) and peginterferon alfa-2a (40 KD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40KD) in patients with chronic hepatitis
    Pockros, PJ
    Pessoa, MG
    Diago, M
    Martinelli, ADC
    Berg, T
    Germanidis, G
    Lai, MY
    Gomez, HR
    Goeser, T
    Roberts, S
    Sheen, IS
    Hsien, T
    Hinrichsen, HM
    Lee, SS
    Reindollar, R
    Sola, R
    Wilson, K
    Jorga, K
    Graham, P
    Jackson, H
    HEPATOLOGY, 2004, 40 (04) : 391A - 391A
  • [9] Long-lasting sustained virological response in chronic hepatitis C patients previously treated with 40 kDa peginterferon alfa-2a (PEGASYS®).
    Swain, M
    Heathcote, EJ
    Lai, MY
    Bain, V
    Feinman, V
    Sherman, M
    Kaita, KD
    Gane, E
    Peltekian, K
    Lindsay, K
    Hoffman, J
    Brunda, M
    HEPATOLOGY, 2001, 34 (04) : 330A - 330A
  • [10] Hepatitis c virus dynamics during therapy with peginterferon ALFA-2A (PEGASYS®) compared to peginterferon ALFA-2B (PEGINTRON®) in naive patients with chronic Hepatitis C.
    Bruno, R
    Debiaggi, M
    Ciappina, V
    Maffezzini, E
    Patruno, S
    Sacchi, P
    Filice, G
    HEPATOLOGY, 2002, 36 (04) : 206A - 206A
12345